MedTrace Logo

A Study of Golimumab in Participants With Active Ankylosing Spondylitis

NCT02186873 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2025-10-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of intravenously (administration of a fluid into the vein) administered golimumab 2 milligram per kilogram (mg/kg) in participants with active ankylosing spondylitis (chronic inflammatory disease of unknown etiology that involves the sacroiliac joints, and often the axial skeleton, entheses, and peripheral joints).

Conditions

Interventions

DRUG

Placebo

Participants will receive matching placebo.

DRUG

Golimumab

Participants will receive 2mg/kg of intravenous infusions of golimumab .

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-03
Primary Completion
2015-12-15
Completion
2016-10-11
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • Mexico
  • Poland
  • Russia
  • South Korea
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02186873 on ClinicalTrials.gov